


**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Previously Presented) A compound of formula (I):



(I)

wherein:

A represents an optionally substituted aryl, or an optionally substituted 5- or 6-membered heterocyclyl ring, or an optionally substituted bicyclic heterocyclyl group;

B represents a phenyl or pyridyl ring;

D represents an optionally substituted 5- or 6-membered heterocyclyl ring containing one or two heteroatoms selected from N, S and O, wherein X and Y are each independently selected from N and C;

Z represents O, S, SO, or SO<sub>2</sub>;

$R^1$  represents CO<sub>2</sub>H, CN, CONR<sup>5</sup>R<sup>6</sup>, CH<sub>2</sub>CO<sub>2</sub>H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted SO<sub>2</sub>alkyl, SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, NR<sup>5</sup>CONR<sup>5</sup>R<sup>6</sup>, COalkyl, 2H-tetrazol-5-yl-methyl, optionally substituted bicyclic heterocycle or optionally substituted heterocyclyl;

$R^{2a}$  and  $R^{2b}$  each independently represents hydrogen, halo, optionally substituted alkyl, optionally substituted alkoxy, CN, SO<sub>2</sub>alkyl, SR<sup>5</sup>, NO<sub>2</sub>, optionally substituted aryl, CONR<sup>5</sup>R<sup>6</sup> or optionally substituted heteroaryl;

$R^x$  represents optionally substituted alkyl wherein 1 or 2 of the non-terminal carbon atoms are optionally substituted by a group independently selected from NR<sup>4</sup>, O and SO<sub>n</sub>, wherein n is 0, 1 or 2; optionally substituted alkenyl; or optionally substituted alkynyl; or  $R^x$  represents optionally substituted CQ<sup>a</sup>Q<sup>b</sup>-

heterocyclyl, optionally substituted  $CQ^aQ^b$ -bicyclic heterocyclyl or optionally substituted  $CQ^aQ^b$ -aryl;

$R^4$  represents hydrogen or an optionally substituted alkyl;

$R^5$  represents hydrogen or an optionally substituted alkyl;

$R^6$  represents hydrogen or optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted  $SO_2$ aryl, optionally substituted  $SO_2$ alkyl, optionally substituted  $SO_2$ heteroaryl, CN, optionally substituted  $CQ^aQ^b$ aryl, optionally substituted  $CQ^aQ^b$ heteroaryl or  $COR^7$ ;


$R^7$  represents hydrogen, optionally substituted alkyl, optionally substituted heteroaryl or optionally substituted aryl;

$Q^a$  and  $Q^b$  are each independently selected from hydrogen and  $CH_3$ ;


wherein when A is a 6-membered ring the  $R^1$  substituent and the D ring are attached to carbon atoms 1,2-, 1,3- or 1,4- relative to each other, and when A is a five-membered ring or bicyclic heterocyclyl group the  $R^1$  substituent and the D ring are attached to substitutable carbon atoms 1,2- or 1,3- relative to each other;

and derivatives thereof;

provided that D is not imidazolyl, thienyl,



2. (Previously Presented) A compound according to claim 1 wherein D is selected from



all of which may be optionally substituted.

3. (Currently Amended) A compound according to claim 1 ~~or claim 2~~ wherein A in is selected from pyridyl or optionally substituted phenyl.
4. (Currently Amended) A compound according to ~~any one of~~ claims 1 to 3 wherein R<sup>1</sup> is CO<sub>2</sub>H.
5. (Previously Presented) A compound selected from:
  - 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid;
  - 3-{1-[2-(benzyloxy)-5-chloro-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid;
  - 3-{1-[2-(benzyloxy)-5-bromo-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid;
  - 3-{5-[2-(benzyloxy)-phenyl]-1H-pyrazol-1-yl}-benzoic acid;
  - 3-{5-[2-(benzyloxy)-5-chloro-phenyl]-1H-pyrazol-1-yl}-benzoic acid;
  - 3-{3-[2-(benzyloxy)-5-chloro-phenyl]-pyrazin-2-yl}-benzoic acid;
  - 3-{4-[2-(benzyloxy)-5-chloro-phenyl]-2-oxo-2,5-dihydro-furan-3-yl}-benzoic acid;
  - 3-{3-[2-(benzyloxy)-5-chloro-phenyl]-2-oxo-2,5-dihydro-furan-4-yl}-benzoic acid;
  - 3-{3-[2-(benzyloxy)-5-chloro-phenyl]-pyridin-4-yl}-benzoic acid;
  - 3-{3-[2-(benzyloxy)-phenyl]-pyridin-4-yl}-benzoic acid;
  - 3-{4-[2-(benzyloxy)-5-chloro-phenyl]-pyridin-3-yl}-benzoic acid;
  - 3-{3-[2-(benzyloxy)-5-chloro-phenyl]-pyridin-2-yl}-benzoic acid;
  - 3-{3-[2-(benzyloxy)-5-(trifluoromethyl)-phenyl]-pyridin-4-yl}-5-(acetylamino)-benzoic acid;
  - 3-{3-[2-(4-fluoro-benzyloxy)-5-(trifluoromethyl)-phenyl]-pyridin-4-yl}-5-(acetylamino)-benzoic acid;
  - 3-{3-[2-(2,4-difluoro-benzyloxy)-5-(trifluoromethyl)-phenyl]-pyridin-4-yl}-5-(acetylamino)-benzoic acid;
  - 3-{3-[2-(benzyloxy)-phenyl]-pyridin-4-yl}-5-(acetylamino)-benzoic acid; and

6-{1-[2-(benzyloxy)-5-chloro-phenyl]-5-methyl-1H-pyrrol-2-yl}-2-pyridinecarboxylic acid;  
and derivatives thereof.

6. (Currently Amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 5~~ or a pharmaceutically acceptable derivative thereof together with a pharmaceutical carrier and/or excipient.

7. – 8. (Canceled).

9. (Currently Amended) A method of treating a human or animal subject suffering from a condition which is mediated by the action of PGE<sub>2</sub> at EP<sub>1</sub> receptors which comprises administering to said subject an effective amount of a compound according to ~~any one of claims 1 to 5~~ or a pharmaceutically acceptable derivative thereof.

10. (Currently Amended) A method of treating a human or animal subject suffering from a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder, which method comprises administering to said subject an effective amount of a compound according to ~~any one of claims 1 to 5~~ or a pharmaceutically acceptable derivative thereof.

11. (Currently Amended) A method of treating a human or animal subject suffering from inflammatory pain, neuropathic pain or visceral pain which method comprises administering to said subject an effective amount of a compound according to ~~any one of claims 1 to 5~~ or a pharmaceutically acceptable derivative thereof.

12. – 14. (Canceled).

15. (New) The method of claim 9 wherein the subject is human.

16. (New) The method of claim 10 wherein the subject is human.

17. (New) The method of claim 11 wherein the subject is human.

18. (New) A method of mediating EP<sub>1</sub> receptors, comprising the step of administering an effective amount of a compound according to claim 1 or a pharmaceutically acceptable derivative thereof.